1	7	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Involvement	_	_	NN	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	Apelin	_	_	NNP	_	_	_	_	_
5	System	_	_	NN	_	_	_	_	_
6	in	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	Pathogenesis	_	_	NNP	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	Liver	_	_	NNP	_	_	_	_	_
11	Fibrosis	_	_	NNP	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	apelin	_	_	NN	_	_	_	_	_
3	system	_	_	NN	_	_	_	_	_
4	has	_	_	VBZ	_	_	_	_	_
5	certain	_	_	JJ	_	_	_	_	_
6	therapeutic	_	_	JJ	_	_	_	_	_
7	abilities	_	_	NNS	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	but	_	_	CC	_	_	_	_	_
10	it	_	_	PRP	_	_	_	_	_
11	may	_	_	MD	_	_	_	_	_
12	also	_	_	RB	_	_	_	_	_
13	play	_	_	VB	_	_	_	_	_
14	a	_	_	DT	_	_	_	_	_
15	role	_	_	NN	_	_	_	_	_
16	in	_	_	IN	_	_	_	_	_
17	disease	_	_	NN	_	_	_	_	_
18	depending	_	_	VBG	_	_	_	_	_
19	on	_	_	IN	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	cellular	_	_	JJ	_	_	_	_	_
22	and	_	_	CC	_	_	_	_	_
23	molecular	_	_	JJ	_	_	_	_	_
24	milieu	_	_	NN	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	A	_	_	DT	_	_	_	_	_
2	clear	_	_	JJ	_	_	_	_	_
3	example	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	this	_	_	DT	_	_	_	_	_
6	is	_	_	VBZ	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	role	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	apelin	_	_	NN	_	_	_	_	_
11	in	_	_	IN	_	_	_	_	_
12	tissue	_	_	NN	_	_	_	_	_
13	fibrosis	_	_	NN	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	Apelin	_	_	NNP	_	_	_	_	_
2	displays	_	_	VBZ	_	_	_	_	_
3	anti-fibrotic	_	_	JJ	_	_	_	_	_
4	actions	_	_	NNS	_	_	_	_	_
5	counteracting	_	_	VBG	_	_	_	_	_
6	AII	_	_	NNP	_	_	_	_	_
7	in	_	_	IN	_	_	_	_	_
8	models	_	_	NNS	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	cardiac	_	_	JJ	_	_	_	_	_
11	fibrosis	_	_	NN	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	renal	_	_	JJ	_	_	_	_	_
14	fibrosis	_	_	NN	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	contrast	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	scenario	_	_	NN	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	role	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	apelin	_	_	NN	_	_	_	_	_
11	system	_	_	NN	_	_	_	_	_
12	are	_	_	VBP	_	_	_	_	_
13	completely	_	_	RB	_	_	_	_	_
14	different	_	_	JJ	_	_	_	_	_
15	in	_	_	IN	_	_	_	_	_
16	liver	_	_	NN	_	_	_	_	_
17	disease	_	_	NN	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	Apelin	_	_	NNP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	hepatic	_	_	JJ	_	_	_	_	_
5	pro-fibrotic	_	_	JJ	_	_	_	_	_
6	agent	_	_	NN	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	part	_	_	NN	_	_	_	_	_
10	by	_	_	IN	_	_	_	_	_
11	mediating	_	_	VBG	_	_	_	_	_
12	some	_	_	DT	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	fibrogenic	_	_	JJ	_	_	_	_	_
16	effects	_	_	NNS	_	_	_	_	_
17	triggered	_	_	VBN	_	_	_	_	_
18	by	_	_	IN	_	_	_	_	_
19	AII	_	_	NNP	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	ET-1	_	_	NNP	_	_	_	_	_
22	in	_	_	IN	_	_	_	_	_
23	the	_	_	DT	_	_	_	_	_
24	activation	_	_	NN	_	_	_	_	_
25	of	_	_	IN	_	_	_	_	_
26	HSC	_	_	NN	_	_	_	_	_
27	occurring	_	_	VBG	_	_	_	_	_
28	in	_	_	IN	_	_	_	_	_
29	liver	_	_	NN	_	_	_	_	_
30	fibrosis	_	_	NN	_	_	_	_	_
31	.	_	_	.	_	_	_	_	_


1	These	_	_	DT	_	_	_	_	_
2	outcomes	_	_	NNS	_	_	_	_	_
3	highlight	_	_	VBP	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	intriguing	_	_	JJ	_	_	_	_	_
6	difference	_	_	NN	_	_	_	_	_
7	between	_	_	IN	_	_	_	_	_
8	myofibroblastic-cell	_	_	JJ	_	_	_	_	_
9	types	_	_	NNS	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	liver	_	_	NN	_	_	_	_	_
12	compared	_	_	VBN	_	_	_	_	_
13	to	_	_	TO	_	_	_	_	_
14	myofibroblasts	_	_	NNS	_	_	_	_	_
15	in	_	_	IN	_	_	_	_	_
16	heart	_	_	NN	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	kidney	_	_	NN	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	or	_	_	CC	_	_	_	_	_
21	skin	_	_	NN	_	_	_	_	_
22	in	_	_	IN	_	_	_	_	_
23	which	_	_	WDT	_	_	_	_	_
24	apelin	_	_	NN	_	_	_	_	_
25	acts	_	_	VBZ	_	_	_	_	_
26	by	_	_	IN	_	_	_	_	_
27	decreasing	_	_	VBG	_	_	_	_	_
28	myofibroblast	_	_	NN	_	_	_	_	_
29	accumulation	_	_	NN	_	_	_	_	_
30	and	_	_	CC	_	_	_	_	_
31	activity	_	_	NN	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	vitro	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	apelin	_	_	NN	_	_	_	_	_
5	has	_	_	VBZ	_	_	_	_	_
6	also	_	_	RB	_	_	_	_	_
7	demonstrated	_	_	VBN	_	_	_	_	_
8	a	_	_	DT	_	_	_	_	_
9	significant	_	_	JJ	_	_	_	_	_
10	potential	_	_	NN	_	_	_	_	_
11	to	_	_	TO	_	_	_	_	_
12	promote	_	_	VB	_	_	_	_	_
13	liver	_	_	NN	_	_	_	_	_
14	fibrosis	_	_	NN	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	acts	_	_	VBZ	_	_	_	_	_
3	directly	_	_	RB	_	_	_	_	_
4	on	_	_	IN	_	_	_	_	_
5	LX-2	_	_	NNP	_	_	_	_	_
6	cells	_	_	NNS	_	_	_	_	_
7	(	_	_	-LRB-	_	_	_	_	_
8	a	_	_	DT	_	_	_	_	_
9	cell	_	_	NN	_	_	_	_	_
10	line	_	_	NN	_	_	_	_	_
11	used	_	_	VBN	_	_	_	_	_
12	as	_	_	IN	_	_	_	_	_
13	a	_	_	DT	_	_	_	_	_
14	reliable	_	_	JJ	_	_	_	_	_
15	in	_	_	IN	_	_	_	_	_
16	vitro	_	_	NN	_	_	_	_	_
17	model	_	_	NN	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	HSC	_	_	NN	_	_	_	_	_
20	)	_	_	-RRB-	_	_	_	_	_
21	through	_	_	IN	_	_	_	_	_
22	Erk	_	_	NNP	_	_	_	_	_
23	signalling	_	_	VBG	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	stimulating	_	_	VBG	_	_	_	_	_
26	cell	_	_	NN	_	_	_	_	_
27	survival	_	_	NN	_	_	_	_	_
28	and	_	_	CC	_	_	_	_	_
29	the	_	_	DT	_	_	_	_	_
30	synthesis	_	_	NN	_	_	_	_	_
31	of	_	_	IN	_	_	_	_	_
32	PDGF-β	_	_	NN	_	_	_	_	_
33	receptor	_	_	NN	_	_	_	_	_
34	and	_	_	CC	_	_	_	_	_
35	collagen-I	_	_	NN	_	_	_	_	_
36	in	_	_	IN	_	_	_	_	_
37	these	_	_	DT	_	_	_	_	_
38	cells	_	_	NNS	_	_	_	_	_
39	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	turn	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	PDGF-β	_	_	NNP	_	_	_	_	_
5	and	_	_	CC	_	_	_	_	_
6	LPS	_	_	NNP	_	_	_	_	_
7	can	_	_	MD	_	_	_	_	_
8	stimulate	_	_	VB	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	expression	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	APJ	_	_	NNP	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	expanding	_	_	VBG	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	perpetuating	_	_	VBG	_	_	_	_	_
17	HSC	_	_	NN	_	_	_	_	_
18	activation	_	_	NN	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	Therefore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	apelin	_	_	NN	_	_	_	_	_
4	may	_	_	MD	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	in	_	_	IN	_	_	_	_	_
7	theory	_	_	NN	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	induce	_	_	VB	_	_	_	_	_
10	HSC	_	_	NNP	_	_	_	_	_
11	to	_	_	TO	_	_	_	_	_
12	a	_	_	DT	_	_	_	_	_
13	pro-fibrogenic	_	_	JJ	_	_	_	_	_
14	profile	_	_	NN	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	prolong	_	_	VB	_	_	_	_	_
17	its	_	_	PRP$	_	_	_	_	_
18	stimulation	_	_	NN	_	_	_	_	_
19	autocrinally	_	_	RB	_	_	_	_	_
20	during	_	_	IN	_	_	_	_	_
21	all	_	_	DT	_	_	_	_	_
22	stages	_	_	NNS	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	liver	_	_	NN	_	_	_	_	_
25	fibrosis	_	_	NN	_	_	_	_	_
26	in	_	_	IN	_	_	_	_	_
27	chronic	_	_	JJ	_	_	_	_	_
28	liver	_	_	NN	_	_	_	_	_
29	disease	_	_	NN	_	_	_	_	_
30	(	_	_	-LRB-	_	_	_	_	_
31	Figure	_	_	NN	_	_	_	_	_
32	6	_	_	CD	_	_	_	_	_
33	)	_	_	-RRB-	_	_	_	_	_
34	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	fact	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	some	_	_	DT	_	_	_	_	_
5	data	_	_	NNS	_	_	_	_	_
6	have	_	_	VBP	_	_	_	_	_
7	revealed	_	_	VBN	_	_	_	_	_
8	that	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	inhibition	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	APJ	_	_	NNP	_	_	_	_	_
13	using	_	_	VBG	_	_	_	_	_
14	F13A	_	_	NNP	_	_	_	_	_
15	(	_	_	-LRB-	_	_	_	_	_
16	an	_	_	DT	_	_	_	_	_
17	APJ	_	_	NNP	_	_	_	_	_
18	antagonist	_	_	NN	_	_	_	_	_
19	)	_	_	-RRB-	_	_	_	_	_
20	prevents	_	_	VBZ	_	_	_	_	_
21	fibrosis	_	_	NN	_	_	_	_	_
22	progression	_	_	NN	_	_	_	_	_
23	in	_	_	IN	_	_	_	_	_
24	rats	_	_	NNS	_	_	_	_	_
25	under	_	_	IN	_	_	_	_	_
26	a	_	_	DT	_	_	_	_	_
27	non-discontinued	_	_	JJ	_	_	_	_	_
28	fibrosis	_	_	NN	_	_	_	_	_
29	induction	_	_	NN	_	_	_	_	_
30	program	_	_	NN	_	_	_	_	_
31	using	_	_	VBG	_	_	_	_	_
32	CCl4	_	_	NNP	_	_	_	_	_
33	.	_	_	.	_	_	_	_	_


1	Several	_	_	JJ	_	_	_	_	_
2	investigations	_	_	NNS	_	_	_	_	_
3	have	_	_	VBP	_	_	_	_	_
4	uncovered	_	_	VBN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	close	_	_	JJ	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	integrated	_	_	VBN	_	_	_	_	_
9	relationship	_	_	NN	_	_	_	_	_
10	between	_	_	IN	_	_	_	_	_
11	pathological	_	_	JJ	_	_	_	_	_
12	angiogenesis	_	_	NN	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	fibrosis	_	_	NN	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	As	_	_	IN	_	_	_	_	_
2	mentioned	_	_	VBN	_	_	_	_	_
3	above	_	_	RB	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	apelin	_	_	NN	_	_	_	_	_
6	is	_	_	VBZ	_	_	_	_	_
7	a	_	_	DT	_	_	_	_	_
8	powerful	_	_	JJ	_	_	_	_	_
9	angiogenic	_	_	JJ	_	_	_	_	_
10	agent	_	_	NN	_	_	_	_	_
11	through	_	_	IN	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	activation	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	endothelial	_	_	JJ	_	_	_	_	_
16	APJ	_	_	NNP	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	different	_	_	JJ	_	_	_	_	_
19	downstream	_	_	JJ	_	_	_	_	_
20	signalling	_	_	NN	_	_	_	_	_
21	pathways	_	_	NNS	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	Two	_	_	CD	_	_	_	_	_
2	reports	_	_	NNS	_	_	_	_	_
3	have	_	_	VBP	_	_	_	_	_
4	associated	_	_	VBN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	inhibition	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	APJ	_	_	NNP	_	_	_	_	_
9	with	_	_	IN	_	_	_	_	_
10	a	_	_	DT	_	_	_	_	_
11	reduction	_	_	NN	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	angiogenesis	_	_	NN	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	with	_	_	IN	_	_	_	_	_
16	a	_	_	DT	_	_	_	_	_
17	concomitant	_	_	JJ	_	_	_	_	_
18	drop	_	_	NN	_	_	_	_	_
19	in	_	_	IN	_	_	_	_	_
20	fibrosis	_	_	NN	_	_	_	_	_
21	in	_	_	IN	_	_	_	_	_
22	CH	_	_	NN	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	fibrotic	_	_	JJ	_	_	_	_	_
25	rats	_	_	NNS	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	Although	_	_	IN	_	_	_	_	_
2	a	_	_	DT	_	_	_	_	_
3	direct	_	_	JJ	_	_	_	_	_
4	relationship	_	_	NN	_	_	_	_	_
5	was	_	_	VBD	_	_	_	_	_
6	not	_	_	RB	_	_	_	_	_
7	established	_	_	VBN	_	_	_	_	_
8	between	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	two	_	_	CD	_	_	_	_	_
11	phenomena	_	_	NNS	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	there	_	_	EX	_	_	_	_	_
14	are	_	_	VBP	_	_	_	_	_
15	evidence	_	_	NN	_	_	_	_	_
16	pointing	_	_	VBG	_	_	_	_	_
17	out	_	_	RP	_	_	_	_	_
18	that	_	_	IN	_	_	_	_	_
19	APJ	_	_	NNP	_	_	_	_	_
20	activation	_	_	NN	_	_	_	_	_
21	by	_	_	IN	_	_	_	_	_
22	apelin	_	_	NN	_	_	_	_	_
23	stimulates	_	_	VBZ	_	_	_	_	_
24	the	_	_	DT	_	_	_	_	_
25	expression	_	_	NN	_	_	_	_	_
26	of	_	_	IN	_	_	_	_	_
27	a	_	_	DT	_	_	_	_	_
28	well-known	_	_	JJ	_	_	_	_	_
29	pro-angiogenic	_	_	JJ	_	_	_	_	_
30	factor	_	_	NN	_	_	_	_	_
31	,	_	_	,	_	_	_	_	_
32	angiopoietin-1	_	_	NN	_	_	_	_	_
33	(	_	_	-LRB-	_	_	_	_	_
34	from	_	_	IN	_	_	_	_	_
35	the	_	_	DT	_	_	_	_	_
36	angiopoietin	_	_	NN	_	_	_	_	_
37	family	_	_	NN	_	_	_	_	_
38	involved	_	_	VBN	_	_	_	_	_
39	in	_	_	IN	_	_	_	_	_
40	pathological	_	_	JJ	_	_	_	_	_
41	angiogenesis	_	_	NN	_	_	_	_	_
42	in	_	_	IN	_	_	_	_	_
43	chronic	_	_	JJ	_	_	_	_	_
44	liver	_	_	NN	_	_	_	_	_
45	disease	_	_	NN	_	_	_	_	_
46	)	_	_	-RRB-	_	_	_	_	_
47	in	_	_	IN	_	_	_	_	_
48	LX-2	_	_	NNP	_	_	_	_	_
49	cells	_	_	NNS	_	_	_	_	_
50	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	suggests	_	_	VBZ	_	_	_	_	_
3	that	_	_	IN	_	_	_	_	_
4	fibrogenic	_	_	JJ	_	_	_	_	_
5	cells	_	_	NNS	_	_	_	_	_
6	such	_	_	JJ	_	_	_	_	_
7	as	_	_	IN	_	_	_	_	_
8	HSC	_	_	NNP	_	_	_	_	_
9	may	_	_	MD	_	_	_	_	_
10	participate	_	_	VB	_	_	_	_	_
11	in	_	_	IN	_	_	_	_	_
12	hepatic	_	_	JJ	_	_	_	_	_
13	angiogenesis	_	_	NN	_	_	_	_	_
14	by	_	_	IN	_	_	_	_	_
15	secreting	_	_	VBG	_	_	_	_	_
16	angiogenic	_	_	JJ	_	_	_	_	_
17	factors	_	_	NNS	_	_	_	_	_
18	such	_	_	JJ	_	_	_	_	_
19	as	_	_	IN	_	_	_	_	_
20	angiopoietin	_	_	NN	_	_	_	_	_
21	1	_	_	CD	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	Indeed	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	inhibition	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	HSC-secreted	_	_	JJ	_	_	_	_	_
7	angiopietin-1	_	_	NN	_	_	_	_	_
8	has	_	_	VBZ	_	_	_	_	_
9	shown	_	_	VBN	_	_	_	_	_
10	to	_	_	TO	_	_	_	_	_
11	drastically	_	_	RB	_	_	_	_	_
12	reduce	_	_	VB	_	_	_	_	_
13	pathological	_	_	JJ	_	_	_	_	_
14	angiogenesis	_	_	NN	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	liver	_	_	NN	_	_	_	_	_
17	fibrosis	_	_	NN	_	_	_	_	_
18	induced	_	_	VBN	_	_	_	_	_
19	in	_	_	IN	_	_	_	_	_
20	mice	_	_	NNS	_	_	_	_	_
21	by	_	_	IN	_	_	_	_	_
22	either	_	_	CC	_	_	_	_	_
23	CCl4	_	_	NNP	_	_	_	_	_
24	or	_	_	CC	_	_	_	_	_
25	BDL	_	_	NNP	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	Aside	_	_	RB	_	_	_	_	_
2	from	_	_	IN	_	_	_	_	_
3	HSC	_	_	NNP	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	hepatocytes	_	_	NNS	_	_	_	_	_
6	have	_	_	VBP	_	_	_	_	_
7	also	_	_	RB	_	_	_	_	_
8	been	_	_	VBN	_	_	_	_	_
9	related	_	_	VBN	_	_	_	_	_
10	to	_	_	TO	_	_	_	_	_
11	contribute	_	_	VB	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	both	_	_	DT	_	_	_	_	_
14	phenomena	_	_	NNS	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	pathological	_	_	JJ	_	_	_	_	_
17	angiogenesis	_	_	NN	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	liver	_	_	NN	_	_	_	_	_
20	fibrosis	_	_	NN	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	by	_	_	IN	_	_	_	_	_
23	releasing	_	_	VBG	_	_	_	_	_
24	pro-angiogenic	_	_	JJ	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	pro-fibrogenic	_	_	JJ	_	_	_	_	_
27	factors	_	_	NNS	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	There	_	_	EX	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	growing	_	_	VBG	_	_	_	_	_
5	belief	_	_	NN	_	_	_	_	_
6	that	_	_	IN	_	_	_	_	_
7	local	_	_	JJ	_	_	_	_	_
8	hypoxia	_	_	NN	_	_	_	_	_
9	is	_	_	VBZ	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	link	_	_	NN	_	_	_	_	_
12	interconnecting	_	_	VBG	_	_	_	_	_
13	both	_	_	CC	_	_	_	_	_
14	pathological	_	_	JJ	_	_	_	_	_
15	angiogenesis	_	_	NN	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	liver	_	_	NN	_	_	_	_	_
18	fibrogenesis	_	_	NN	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	orchestrating	_	_	VBG	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	harmonic	_	_	JJ	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	coordinated	_	_	VBN	_	_	_	_	_
25	activation	_	_	NN	_	_	_	_	_
26	of	_	_	IN	_	_	_	_	_
27	HSC	_	_	NN	_	_	_	_	_
28	,	_	_	,	_	_	_	_	_
29	hepatocytes	_	_	NNS	_	_	_	_	_
30	and	_	_	CC	_	_	_	_	_
31	other	_	_	JJ	_	_	_	_	_
32	hepatic	_	_	JJ	_	_	_	_	_
33	cells	_	_	NNS	_	_	_	_	_
34	.	_	_	.	_	_	_	_	_


1	Detection	_	_	NN	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	hypoxic	_	_	JJ	_	_	_	_	_
4	areas	_	_	NNS	_	_	_	_	_
5	is	_	_	VBZ	_	_	_	_	_
6	a	_	_	DT	_	_	_	_	_
7	common	_	_	JJ	_	_	_	_	_
8	trait	_	_	NN	_	_	_	_	_
9	at	_	_	IN	_	_	_	_	_
10	any	_	_	DT	_	_	_	_	_
11	stage	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	chronic	_	_	JJ	_	_	_	_	_
14	liver	_	_	NN	_	_	_	_	_
15	disease	_	_	NN	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	expanding	_	_	VBG	_	_	_	_	_
18	progressively	_	_	RB	_	_	_	_	_
19	from	_	_	IN	_	_	_	_	_
20	early	_	_	JJ	_	_	_	_	_
21	injury	_	_	NN	_	_	_	_	_
22	to	_	_	TO	_	_	_	_	_
23	the	_	_	DT	_	_	_	_	_
24	development	_	_	NN	_	_	_	_	_
25	of	_	_	IN	_	_	_	_	_
26	cirrhosis	_	_	NN	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_
28	,	_	_	,	_	_	_	_	_
29	Through	_	_	IN	_	_	_	_	_
30	the	_	_	DT	_	_	_	_	_
31	action	_	_	NN	_	_	_	_	_
32	of	_	_	IN	_	_	_	_	_
33	hypoxia-inducible	_	_	JJ	_	_	_	_	_
34	factors	_	_	NNS	_	_	_	_	_
35	(	_	_	-LRB-	_	_	_	_	_
36	HIF	_	_	NN	_	_	_	_	_
37	)	_	_	-RRB-	_	_	_	_	_
38	,	_	_	,	_	_	_	_	_
39	hepatic	_	_	JJ	_	_	_	_	_
40	hypoxia	_	_	NN	_	_	_	_	_
41	up-regulates	_	_	VBZ	_	_	_	_	_
42	the	_	_	DT	_	_	_	_	_
43	expression	_	_	NN	_	_	_	_	_
44	of	_	_	IN	_	_	_	_	_
45	a	_	_	DT	_	_	_	_	_
46	wide	_	_	JJ	_	_	_	_	_
47	array	_	_	NN	_	_	_	_	_
48	of	_	_	IN	_	_	_	_	_
49	growth	_	_	NN	_	_	_	_	_
50	factors	_	_	NNS	_	_	_	_	_
51	and	_	_	CC	_	_	_	_	_
52	mediators	_	_	NNS	_	_	_	_	_
53	of	_	_	IN	_	_	_	_	_
54	liver	_	_	NN	_	_	_	_	_
55	repair	_	_	NN	_	_	_	_	_
56	and	_	_	CC	_	_	_	_	_
57	angiogenesis	_	_	NN	_	_	_	_	_
58	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	pathological	_	_	JJ	_	_	_	_	_
4	angiogenesis	_	_	NN	_	_	_	_	_
5	can	_	_	MD	_	_	_	_	_
6	be	_	_	VB	_	_	_	_	_
7	inefficient	_	_	JJ	_	_	_	_	_
8	due	_	_	JJ	_	_	_	_	_
9	to	_	_	TO	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	immaturity	_	_	NN	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	permeability	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	vascular	_	_	JJ	_	_	_	_	_
16	endothelial	_	_	JJ	_	_	_	_	_
17	growth	_	_	NN	_	_	_	_	_
18	factor	_	_	NN	_	_	_	_	_
19	(	_	_	-LRB-	_	_	_	_	_
20	VEGF)-induced	_	_	JJ	_	_	_	_	_
21	new	_	_	JJ	_	_	_	_	_
22	vessels	_	_	NNS	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	consequently	_	_	RB	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	the	_	_	DT	_	_	_	_	_
28	liver	_	_	NN	_	_	_	_	_
29	may	_	_	MD	_	_	_	_	_
30	be	_	_	VB	_	_	_	_	_
31	unable	_	_	JJ	_	_	_	_	_
32	to	_	_	TO	_	_	_	_	_
33	reduce	_	_	VB	_	_	_	_	_
34	hypoxia	_	_	NN	_	_	_	_	_
35	.	_	_	.	_	_	_	_	_


1	Hypoxia	_	_	NN	_	_	_	_	_
2	up-regulates	_	_	VBZ	_	_	_	_	_
3	in	_	_	IN	_	_	_	_	_
4	vitro	_	_	FW	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	expression	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	APJ	_	_	NNP	_	_	_	_	_
9	in	_	_	IN	_	_	_	_	_
10	LX-2	_	_	NNP	_	_	_	_	_
11	(	_	_	-LRB-	_	_	_	_	_
12	HSC	_	_	NNP	_	_	_	_	_
13	)	_	_	-RRB-	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	in	_	_	IN	_	_	_	_	_
16	HepG2	_	_	NNP	_	_	_	_	_
17	(	_	_	-LRB-	_	_	_	_	_
18	hepatocytes	_	_	NNS	_	_	_	_	_
19	)	_	_	-RRB-	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	Interestingly	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	pro-inflammatory	_	_	JJ	_	_	_	_	_
5	and	_	_	CC	_	_	_	_	_
6	pro-fibrogenic	_	_	JJ	_	_	_	_	_
7	agents	_	_	NNS	_	_	_	_	_
8	TNF-α	_	_	NNP	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	AII	_	_	NNP	_	_	_	_	_
11	also	_	_	RB	_	_	_	_	_
12	induce	_	_	VBP	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	expression	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	APJ	_	_	NNP	_	_	_	_	_
17	in	_	_	IN	_	_	_	_	_
18	HepG2	_	_	NNP	_	_	_	_	_
19	cells	_	_	NNS	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	APJ	_	_	NNP	_	_	_	_	_
2	activation	_	_	NN	_	_	_	_	_
3	in	_	_	IN	_	_	_	_	_
4	HepG2	_	_	NNP	_	_	_	_	_
5	cells	_	_	NNS	_	_	_	_	_
6	triggers	_	_	VBZ	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	expression	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	VEGF-A	_	_	NN	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	PDGF-β	_	_	NN	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	factors	_	_	NNS	_	_	_	_	_
15	that	_	_	WDT	_	_	_	_	_
16	in	_	_	IN	_	_	_	_	_
17	turn	_	_	NN	_	_	_	_	_
18	may	_	_	MD	_	_	_	_	_
19	promote	_	_	VB	_	_	_	_	_
20	angiogenesis	_	_	NN	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	activation	_	_	NN	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	HSC	_	_	NN	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	consequently	_	_	RB	_	_	_	_	_
28	,	_	_	,	_	_	_	_	_
29	liver	_	_	NN	_	_	_	_	_
30	fibrosis	_	_	NN	_	_	_	_	_
31	.	_	_	.	_	_	_	_	_


1	According	_	_	VBG	_	_	_	_	_
2	to	_	_	TO	_	_	_	_	_
3	these	_	_	DT	_	_	_	_	_
4	data	_	_	NNS	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	hypoxia	_	_	NN	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	inflammation	_	_	NN	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	pro-fibrogenic	_	_	JJ	_	_	_	_	_
11	factors	_	_	NNS	_	_	_	_	_
12	up-regulate	_	_	JJ	_	_	_	_	_
13	APJ	_	_	NNP	_	_	_	_	_
14	in	_	_	IN	_	_	_	_	_
15	HSC	_	_	NN	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	hepatocytes	_	_	NNS	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	which	_	_	WDT	_	_	_	_	_
20	can	_	_	MD	_	_	_	_	_
21	release	_	_	VB	_	_	_	_	_
22	different	_	_	JJ	_	_	_	_	_
23	pro-angiogenic	_	_	JJ	_	_	_	_	_
24	and	_	_	CC	_	_	_	_	_
25	pro-fibrogenic	_	_	JJ	_	_	_	_	_
26	factors	_	_	NNS	_	_	_	_	_
27	such	_	_	JJ	_	_	_	_	_
28	as	_	_	IN	_	_	_	_	_
29	apelin	_	_	NN	_	_	_	_	_
30	(	_	_	-LRB-	_	_	_	_	_
31	from	_	_	IN	_	_	_	_	_
32	activated	_	_	VBN	_	_	_	_	_
33	HSC	_	_	NN	_	_	_	_	_
34	)	_	_	-RRB-	_	_	_	_	_
35	together	_	_	RB	_	_	_	_	_
36	to	_	_	TO	_	_	_	_	_
37	perpetuate	_	_	VB	_	_	_	_	_
38	fibrosis	_	_	NN	_	_	_	_	_
39	while	_	_	IN	_	_	_	_	_
40	injury	_	_	NN	_	_	_	_	_
41	and	_	_	CC	_	_	_	_	_
42	these	_	_	DT	_	_	_	_	_
43	stimuli	_	_	NNS	_	_	_	_	_
44	remain	_	_	VBP	_	_	_	_	_
45	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	vivo	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	APJ	_	_	NNP	_	_	_	_	_
5	is	_	_	VBZ	_	_	_	_	_
6	upregulated	_	_	VBN	_	_	_	_	_
7	preferentially	_	_	RB	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	hepatocytes	_	_	NNS	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	HSC	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	while	_	_	IN	_	_	_	_	_
14	apelin	_	_	NN	_	_	_	_	_
15	levels	_	_	NNS	_	_	_	_	_
16	are	_	_	VBP	_	_	_	_	_
17	increased	_	_	VBN	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	localized	_	_	VBN	_	_	_	_	_
20	in	_	_	IN	_	_	_	_	_
21	HSC	_	_	NN	_	_	_	_	_
22	in	_	_	IN	_	_	_	_	_
23	cirrhotic	_	_	JJ	_	_	_	_	_
24	rats	_	_	NNS	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	in	_	_	IN	_	_	_	_	_
27	patients	_	_	NNS	_	_	_	_	_
28	with	_	_	IN	_	_	_	_	_
29	liver	_	_	NN	_	_	_	_	_
30	cirrhosis	_	_	NN	_	_	_	_	_
31	caused	_	_	VBN	_	_	_	_	_
32	by	_	_	IN	_	_	_	_	_
33	hepatitis	_	_	NN	_	_	_	_	_
34	C	_	_	NN	_	_	_	_	_
35	virus	_	_	NN	_	_	_	_	_
36	or	_	_	CC	_	_	_	_	_
37	ethanol	_	_	NN	_	_	_	_	_
38	.	_	_	.	_	_	_	_	_


1	High	_	_	JJ	_	_	_	_	_
2	apelin	_	_	NN	_	_	_	_	_
3	levels	_	_	NNS	_	_	_	_	_
4	and	_	_	CC	_	_	_	_	_
5	liver	_	_	NN	_	_	_	_	_
6	damage	_	_	NN	_	_	_	_	_
7	have	_	_	VBP	_	_	_	_	_
8	also	_	_	RB	_	_	_	_	_
9	been	_	_	VBN	_	_	_	_	_
10	observed	_	_	VBN	_	_	_	_	_
11	in	_	_	IN	_	_	_	_	_
12	human	_	_	JJ	_	_	_	_	_
13	non-alcoholic	_	_	JJ	_	_	_	_	_
14	fatty	_	_	NN	_	_	_	_	_
15	liver	_	_	NN	_	_	_	_	_
16	disease	_	_	NN	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	A	_	_	DT	_	_	_	_	_
2	contemporary	_	_	JJ	_	_	_	_	_
3	clinical	_	_	JJ	_	_	_	_	_
4	investigation	_	_	NN	_	_	_	_	_
5	revealed	_	_	VBD	_	_	_	_	_
6	that	_	_	IN	_	_	_	_	_
7	circulating	_	_	VBG	_	_	_	_	_
8	apelin	_	_	NN	_	_	_	_	_
9	levels	_	_	NNS	_	_	_	_	_
10	are	_	_	VBP	_	_	_	_	_
11	associated	_	_	VBN	_	_	_	_	_
12	with	_	_	IN	_	_	_	_	_
13	histological	_	_	JJ	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	hemodynamic	_	_	JJ	_	_	_	_	_
16	features	_	_	NNS	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	chronic	_	_	JJ	_	_	_	_	_
19	liver	_	_	NN	_	_	_	_	_
20	disease	_	_	NN	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	but	_	_	CC	_	_	_	_	_
23	more	_	_	RBR	_	_	_	_	_
24	clinical	_	_	JJ	_	_	_	_	_
25	studies	_	_	NNS	_	_	_	_	_
26	are	_	_	VBP	_	_	_	_	_
27	needed	_	_	VBN	_	_	_	_	_
28	to	_	_	TO	_	_	_	_	_
29	confirm	_	_	VB	_	_	_	_	_
30	the	_	_	DT	_	_	_	_	_
31	major	_	_	JJ	_	_	_	_	_
32	relevance	_	_	NN	_	_	_	_	_
33	of	_	_	IN	_	_	_	_	_
34	apelin	_	_	NN	_	_	_	_	_
35	system	_	_	NN	_	_	_	_	_
36	in	_	_	IN	_	_	_	_	_
37	human	_	_	JJ	_	_	_	_	_
38	liver	_	_	NN	_	_	_	_	_
39	fibrosis	_	_	NN	_	_	_	_	_
40	.	_	_	.	_	_	_	_	_

